Amphastar Pharmaceuticals Inc (AMPH, Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Amphastar Pharmaceuticals Inc is a specialty pharmaceutical company engaged in developing, manufacturing, marketing and selling generic and proprietary injectable & inhalation products. Its products are used in hospitals or urgent care clinical settings. Amphastar Pharmaceuticals Inc has a market cap of $955.938 million; its shares were traded at around $20.50 with and P/S ratio of 3.68.
For the last quarter Amphastar Pharmaceuticals Inc reported a revenue of $89.7 million, compared with the revenue of $60.40 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $294.7 million, an increase of 22.7% from last year. For the last five years Amphastar Pharmaceuticals Inc had an average revenue growth rate of 4.9% a year.
The reported loss per diluted share was 12 cents for the year, compared with the earnings per share of $0.22 in the previous year. The Amphastar Pharmaceuticals Inc had an operating margin of -2.93%, compared with the operating margin of -1.47% a year before. The 10-year historical median operating margin of Amphastar Pharmaceuticals Inc is -1.47%. The profitability rank of the company is 3 (out of 10).
At the end of the fiscal year, Amphastar Pharmaceuticals Inc has the cash and cash equivalents of $86.3 million, compared with $65.6 million in the previous year. The long term debt was $32.0 million, compared with $40.8 million in the previous year. Amphastar Pharmaceuticals Inc has a financial strength rank of 6 (out of 10).
At the current stock price of $20.50, Amphastar Pharmaceuticals Inc is traded at 21.1% premium to its historical median P/S valuation band of $16.93. The P/S ratio of the stock is 3.68, while the historical median P/S ratio is 3.04. The stock gained 1.28% during the past 12 months.
CFO Recent Trades:
- CFO, SVP & Treasurer William J Peters sold 1,500 shares of AMPH stock on 03/04/2019 at the average price of $25.36. The price of the stock has decreased by 19.16% since.
- CFO, SVP & Treasurer William J Peters sold 10,016 shares of AMPH stock on 02/15/2019 at the average price of $24.37. The price of the stock has decreased by 15.88% since.
Directors and Officers Recent Trades:
- President and General Counsel Jason B. Shandell sold 7,500 shares of AMPH stock on 03/01/2019 at the average price of $24.99. The price of the stock has decreased by 17.97% since.
- EVP, Production Center Rong Zhou sold 3,200 shares of AMPH stock on 03/01/2019 at the average price of $25. The price of the stock has decreased by 18% since.
- SVP Corp Admin Center Yakob Liawatidewi sold 8,868 shares of AMPH stock on 02/14/2019 at the average price of $23.86. The price of the stock has decreased by 14.08% since.
- President and General Counsel Jason B. Shandell sold 7,519 shares of AMPH stock on 02/14/2019 at the average price of $23.99. The price of the stock has decreased by 14.55% since.
For the complete 20-year historical financial data of AMPH, click here.
